City Therapeutics Stock: Balance Sheet and Debt
CTYCity Therapeutics has a debt to equity ratio of 0.59 and an interest coverage of over 100x. On paper, City Therapeutics would need 3 years of free cash flow like 2019 to pay off net debt of $5.95B.
Daily figure as of 20 Nov 2026
Balance Sheet Over Time
In all 10 fiscal years since 2010 debt exceeded cash. Interest coverage rose from 4.5x in 2014 to over 100x.
Total Assets and Equity Ratio
How large the balance sheet of City Therapeutics Inc. is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2005 | no data | not reported separately | not reported separately | no data | $7.7B |
| 2006 | $14.85B | not reported separately | not reported separately | 11.6% | $7.29B |
| 2007 | $700M | not reported separately | not reported separately | 139.6% | $7.59B |
| 2008 | $307M | not reported separately | not reported separately | 256.0% | $7.61B |
| 2009 | $1.17B | not reported separately | not reported separately | 26.8% | $7.94B |
| 2010 | $221M | not reported separately | not reported separately | −376.0% | $7.21B |
| 2011 | $17.39B | $14.55B | $9.45B | 56.9% | $8.32B |
| 2012 | $16.71B | $13.75B | $9.37B | 59.7% | $7.62B |
| 2013 | $16.01B | $10.36B | $9.35B | 60.0% | $7.54B |
| 2014 | $22.46B | $12.39B | $9.35B | 40.9% | $7.37B |
| 2015 | $21.47B | $11.79B | $9.35B | 41.5% | $7.24B |
| 2016 | $21.15B | $11.23B | $9.35B | 41.1% | $7.26B |
| 2017 | $20.87B | $10.72B | $9.36B | 44.7% | $7.28B |
| 2018 | $20.58B | $10.25B | $9.36B | 47.9% | $5.95B |
| 2019 | $21B | $9.83B | $9.36B | 48.2% | $5.95B |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.
Equity and Debt
What the Company Owns and Owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2005 | $32M | $2.34B | $7.73B | 3.31 |
| 2006 | $316M | $1.73B | $7.61B | 4.4 |
| 2007 | $44M | $977M | $7.63B | 7.81 |
| 2008 | $41M | $786M | $7.65B | 9.74 |
| 2009 | $17M | $312M | $7.96B | 25.5 |
| 2010 | $5M | −$831M | $7.21B | −8.68 |
| 2011 | $3M | $9.89B | $8.33B | 0.84 |
| 2012 | $8M | $9.97B | $7.63B | 0.76 |
| 2013 | $14M | $9.61B | $7.56B | 0.79 |
| 2014 | $6M | $9.18B | $7.38B | 0.8 |
| 2015 | $3M | $8.91B | $7.24B | 0.81 |
| 2016 | $5M | $8.69B | $7.26B | 0.84 |
| 2017 | $1M | $9.34B | $7.28B | 0.78 |
| 2018 | $5M | $9.87B | $5.96B | 0.6 |
| 2019 | $2M | $10.12B | $5.95B | 0.59 |
Debt of Industry Peers
City Therapeutics's debt to equity is higher than that of 179 of 221 other stocks in the Biotechnology industry.
| Stock | Debt to equity | Equity ratio |
|---|---|---|
| SpyGlass Pharma | no data | no data |
| Vor Biopharma | no data | no data |
| Structure Therapeutics | 0.00 | 95.7% |
| Seaport Therapeutics | no data | no data |
| City Therapeutics | 0.59 | 48.2% |
| Solid Biosciences | 0.12 | 77.4% |
| Inventiva | no data | no data |
| MoonLake Immunotherapeutics | 0.25 | 71.7% |
| Silence Therapeutics | 0.00 | 47.4% |
Figures from the latest fiscal year. The eight peers closest in market value, largest first.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
